Bank of Montreal Can Sells 260,409 Shares of Koninklijke Philips N.V. $PHG

Bank of Montreal Can decreased its position in Koninklijke Philips N.V. (NYSE:PHG) by 85.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,338 shares of the technology company’s stock after selling 260,409 shares during the quarter. Bank of Montreal Can’s holdings in Koninklijke Philips were worth $1,063,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Fiduciary Management Inc. WI grew its holdings in Koninklijke Philips by 21.7% in the 1st quarter. Fiduciary Management Inc. WI now owns 7,515,737 shares of the technology company’s stock valued at $190,900,000 after buying an additional 1,339,055 shares in the last quarter. Investment Management Associates Inc. ADV acquired a new position in shares of Koninklijke Philips in the second quarter valued at about $12,122,000. Dimensional Fund Advisors LP increased its position in Koninklijke Philips by 2.5% during the first quarter. Dimensional Fund Advisors LP now owns 4,396,095 shares of the technology company’s stock worth $111,662,000 after acquiring an additional 106,044 shares during the period. Northern Trust Corp increased its position in Koninklijke Philips by 5.1% during the first quarter. Northern Trust Corp now owns 1,690,402 shares of the technology company’s stock worth $42,936,000 after acquiring an additional 81,653 shares during the period. Finally, ABC Arbitrage SA raised its stake in Koninklijke Philips by 183.9% in the 1st quarter. ABC Arbitrage SA now owns 101,108 shares of the technology company’s stock worth $2,568,000 after purchasing an additional 65,490 shares in the last quarter. 13.67% of the stock is owned by institutional investors and hedge funds.

Koninklijke Philips Price Performance

Shares of NYSE:PHG opened at $28.62 on Friday. The company has a current ratio of 1.32, a quick ratio of 0.86 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $27.56 billion, a PE ratio of 143.11, a PEG ratio of 0.76 and a beta of 0.82. The firm has a 50 day moving average of $28.02 and a 200-day moving average of $26.02. Koninklijke Philips N.V. has a 12 month low of $21.48 and a 12 month high of $29.54.

Koninklijke Philips (NYSE:PHG) last announced its quarterly earnings data on Tuesday, November 4th. The technology company reported $0.37 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.37. Koninklijke Philips had a net margin of 1.07% and a return on equity of 12.14%. The business had revenue of $4.94 billion for the quarter, compared to analysts’ expectations of $4.30 billion. On average, equities research analysts predict that Koninklijke Philips N.V. will post 1.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on PHG shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Koninklijke Philips in a report on Thursday. Wall Street Zen lowered Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Koninklijke Philips presently has a consensus rating of “Buy”.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.